[Comment]: One comment objected that our cost estimates for the various premarket review pathways come from “unknown ‘experts’ in FDA’s Center for Tobacco Products” and that “no data, studies, reports or other reference materials are cited to justify these figures, nor are any substantiated equations or methodological notes provided.”
[Response]: FDA continues to believe that FDA’s experience with premarket submissions for currently regulated tobacco products provides the closest approximation to premarket submissions for newly deemed tobacco products. Furthermore, reviewers in the Center for Tobacco Products are among the most qualified individuals to estimate these costs. FDA welcomed comments on the topic of the cost of premarket submissions and responds elsewhere to specific points made in those comments.
"Reviewers in the Center for Tobacco Products are among the most qualified individuals to estimate these costs." Oh! Skippy got a promotion! I guess that counting logos thing paid off!